LOVENBERG WALTER M PHD 4
4 · MERRIMACK PHARMACEUTICALS INC · Filed Apr 5, 2012
Insider Transaction Report
Form 4
LOVENBERG WALTER M PHD
Director
Transactions
- Purchase
Common Stock
2012-04-03$7.00/sh+1,428$9,996→ 71,428 total - Conversion
Common Stock
2012-04-03+7,143→ 78,571 total - Conversion
Series D Convertible Preferred Stock
2012-04-03−7,143→ 0 total→ Common Stock (7,143 underlying)
Footnotes (1)
- [F1]Each share of Series D Convertible Preferred Stock automatically converted into one share of Common Stock upon the closing of the issuer's initial public offering and had no expiration date.